An international survey of cancer doctors shows many question U.S. health advisers’ 2010 rejection of Roche’s drug Avastin to treat advanced breast cancer. The small survey, published in the journal Cancer, shows almost half of the respondents would continue to use the drug under certain circumstances regardless of the final decision from the Food and Drug Administration.
